CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2021. The put-call ratio across all filers is 1.14 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $70,581 | -40.0% | 1,555 | -25.8% | 0.00% | -25.0% |
| Q2 2023 | $117,725 | -2.6% | 2,097 | -21.5% | 0.00% | 0.0% |
| Q1 2023 | $120,808 | +37.7% | 2,671 | +23.8% | 0.00% | +33.3% |
| Q4 2022 | $87,722 | -44.8% | 2,158 | -11.7% | 0.00% | -50.0% |
| Q3 2022 | $159,000 | -12.2% | 2,445 | -18.2% | 0.01% | 0.0% |
| Q2 2022 | $181,000 | +144.6% | 2,988 | +203.0% | 0.01% | +200.0% |
| Q4 2021 | $74,000 | -16.9% | 986 | +23.9% | 0.00% | -33.3% |
| Q3 2021 | $89,000 | -4.3% | 796 | +37.0% | 0.00% | -40.0% |
| Q2 2021 | $93,000 | +82.4% | 581 | +37.7% | 0.01% | +66.7% |
| Q1 2021 | $51,000 | – | 422 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
| NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
| ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
| Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
| CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
| Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
| HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
| Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
| EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |